INNV

Business Context and Reporting Period

Company: InnovAge Holding Corp. (INNV)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended March 31, 2025
Business Overview: InnovAge is the largest PACE (Program of All-Inclusive Care for the Elderly) provider in the U.S., serving approximately 7,530 frail, dual-eligible seniors across 20 centers in six states. The company operates on a fully capitated model, bearing 100% of the financial risk for participant healthcare costs.

Key Financial Metrics

Liquidity: As of March 31, 2025, the company held $60.5 million in cash and cash equivalents and $41.3 million in short-term investments. The company has $94.8 million of remaining borrowing capacity under its Revolving Credit Facility.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 13.0% year-over-year (YoY) for the quarter and 12.0% for the nine-month period, driven by a 10.7% increase in member months and higher capitation rates.
• Widening GAAP Loss: Net loss for the nine months ended March 31, 2025, increased to $30.3 million from $21.0 million in the prior year. This was significantly impacted by a $10.7 million accrual for a stockholder lawsuit settlement and an $8.5 million impairment charge.
• Expense Increases: Corporate, general, and administrative (G&A) expenses rose 40.1% for the quarter and 15.3% for the nine months, primarily due to the lawsuit accrual and increased compensation costs. Cost of care increased 17.6% (quarter) and 16.8% (nine months) due to higher wages and headcount.
• Impairment Charges: The company recorded an $8.5 million impairment of right-of-use assets and construction in progress related to halting development of a planned de novo center in Louisville, Kentucky.
• Acquisitions: Completed the acquisition of pharmacy assets from Tabula Rasa Healthcare Group (TRHC) for $4.8 million in January 2025.

Guidance, Outlook, and Risks

Management Commentary:

• Cost Pressures: Management anticipates continued increases in the cost of care due to wage inflation, labor shortages, and third-party provider rate increases (particularly in California due to SB 525).
• Enrollment Challenges: The company faces delays in Medicaid redetermination and new enrollments, particularly in California, which may impact revenue timing and PMPM estimates.
• Expansion: State attestations for planned de novo centers in Downey and Bakersfield, California, are currently suspended pending remediation of deficiencies at existing centers.

Key Risks and Contingencies:

• Legal Proceedings: A putative class action lawsuit regarding the IPO has reached a binding term sheet for a $27.0 million settlement; the company has accrued $10.7 million for its share. Final court approval is expected no earlier than Q1 fiscal 2026.
• Regulatory Investigations: The company is cooperating with civil investigative demands from the DOJ and the Colorado Attorney General regarding billing and enrollment practices.
• Debt Maturity: The $60.9 million Term Loan Facility matures on March 8, 2026, and is classified as current. The company intends to refinance or extend this debt.

Investor Verification Checklist

• Settlement Finality: Verify the status of the $27.0 million stockholder lawsuit settlement and the likelihood of court approval.
• Debt Refinancing: Assess the company's ability to refinance the $60.9 million term loan maturing in March 2026 given current interest rates and leverage ratios.
• California Operations: Monitor the resolution of regulatory deficiencies in Sacramento and San Bernardino to determine if the Downey and Bakersfield de novo centers can proceed.
• Cost of Care Trends: Track the impact of California's SB 525 and general wage inflation on the company's cost of care per participant versus capitation rates.
• Enrollment Delays: Evaluate the long-term impact of state-level Medicaid processing delays on census growth and revenue recognition.